Charles Schwab Investment Management Inc Zai Lab LTD Transaction History

Charles Schwab Investment Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$22.28 - $38.71 $40,326 - $70,065	1,810 Added 1.41%	129,927 $3.99 Million
Q3 2022 Nov 14, 2022	BUY	$34.2 - $51.69 $1.67 Million - $2.52 Million	48,736 Added 61.4%	128,117 $4.38 Million
Q2 2022 Aug 15, 2022	BUY	$23.14 - $49.68 $39,916 - $85,698	1,725 Added 2.22%	79,381 $2.75 Million
Q1 2022 May 13, 2022	SELL	$27.77 - $64.4 $40,238 - $93,315	-1,449 Reduced 1.83%	77,656 $3.42 Million
Q4 2021 Feb 11, 2022	BUY	$54.9 - $105.21 $140,818 - $269,863	2,565 Added 3.35%	79,105 $4.97 Million
Q3 2021 Nov 16, 2021	BUY	$105.0 - $178.37 $170,625 - $289,851	1,625 Added 2.17%	76,540 $8.07 Million
Q2 2021 Aug 16, 2021	SELL	$125.11 - $180.0 $1.37 Million - $1.97 Million	-10,934 Reduced 12.74%	74,915 $13.3 Million
Q1 2021 May 17, 2021	BUY	$126.27 - $191.71 $362,016 - $549,632	2,867 Added 3.45%	85,849 $11.5 Million
Q4 2020 Feb 16, 2021	BUY	$81.94 - $135.34 $231,480 - $382,335	2,825 Added 3.52%	82,982 $11.2 Million
Q3 2020 Nov 13, 2020	BUY	$73.3 - $89.48 $5.88 Million - $7.17 Million	80,157 New	80,157 $6.67 Million

125

49.6M

223K

588K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.72B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.